Director/PDMR Shareholding

Coiled Therapeutics PLC

28 September 2026

 

28 September 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Director/PDMR Shareholding

Coiled Therapeutics (AIM: COIL / OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, advises that Stephen West, Non-Executive Director, has today purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:

Number of Ordinary Shares Acquired	Average Price Paid per Ordinary Share	Total Consideration Paid (including charges)	Number of Ordinary Shares Now Held	% of Company's Issued Capital
531,743	7.52 pence	£40,016.77	2,700,368	0.63%

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

-ENDS-

Enquiries:

Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO)	Via Burson Buchanan
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	[phone]
Shore Capital Stockbrokers Limited (Joint Broker) David Coaten / Sophie Collins	[phone]
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino	[phone]
Burson Buchanan (Public Relations)	[phone]
Henry Harrison Topham / Jamie Hooper / Toto Berger
Harbor Access (US Investor Relations)	[phone]
Matt Kelly / Jonathan Paterson

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in an ongoing Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy focuses on generating evidence in selected tumour types, including ovarian and prostate cancer, to support potential pharmaceutical partnerships. Its broader pipeline includes a STAT-6 siRNA programme for immunology indications.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.

By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.

The Company is currently enrolling patients in dose-escalation cohorts evaluating the new lipid-based softgel formulation of AO-252. Phase I/II dose-expansion cohorts in ovarian and prostate cancer are planned to follow once the optimal dose has been established.

For more information, please visit: www.coiledplc.com and follow us on LinkedIn.

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stephen West
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Coiled Therapeutics plc
b)	LEI	254900P4SISIWOR9RH34
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.01 par value ISIN: GB00BSHRN331
b)	Nature of the transaction	Purchase of 531,743 Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		7.399 pence per share	270,306
		7.650 pence per share	261,437
d	Aggregated information - Aggregated volume - Price	-       531,743 -       7.52p
e)	Date of the transactions	28 September 2026
f)	Place of the transactions	London Stock Exchange (XLON); AIM

 

END